0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover488.07%IV-77.15%PremiumDec 20, 2024Expiry Date8.44Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9633Delta0.0058Gamma1.25Leverage Ratio-0.0225Theta0.0012Rho1.20Eff Leverage0.0023Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet